Shots:

• Novartis has discontinued its clinical trial HCQs due to feasibility of recruitment. The recruitment challenge has made it unlikely that the clinical team will be able to collect meaningful data in a reasonable timeframe to determine the effectiveness of HCQ in treating patients with COVID-19
• Novartis will continue to supply HCQ for ongoing IITs on government request globally and will continue to monitor ongoing guidance from health authorities on the further study of HCQ- as well as the decision by the US FDA to stop the EUA of HCQ for COVID-19 treatment
• Novartis will continue to collaborate to find answers for COVID-19 through various partnerships with multi-stakeholder external consortia

Click here to read full press release/ article 

 Ref: Novartis | Image: Novartis